N
Neuromity Therapeutics
Neuromity is pioneering treatments for neurological disorders using deuterium-enabled chiral switching (DECS)
About Neuromity Therapeutics
Neuromity Therapeutics, Inc., founded in 2021, was a pharmaceutical development company that focused on treatments for neurological disorders. The firm was established as one of three companies, including Deuteria Pharmaceuticals, Inc. and DeuteRx, LLC, that grew out of pioneering work in Deuterium-Enabled Chiral Switching (DECS) since 2010. This process involves strategically substituting hydrogen with deuterium at a chiral center in racemic drugs to create more stable and superior therapeutic agents.
The company's core strategy was to leverage the DECS platform to reduce development risk, shorten research timelines, and lower development costs while creating new intellectual property. Neuromity's lead compound was NTY-184, a deuterium-stabilized S-bupropion intended for the treatment of major depressive disorder. The business model centered on developing these improved drugs to provide new therapeutic options for patients with neurological conditions. It operated within the HealthTech and Life Sciences sectors. While information about specific founders is not publicly detailed, the company was an outcome of the team behind DeuteRx, LLC, which has a track record of creating and selling assets to major pharmaceutical companies like Celgene, Poxel SA, and Salarius Pharmaceuticals.
Based in Boston, Massachusetts, Neuromity Therapeutics was a venture-capital-backed entity. However, as of July 2024, the company is listed as out of business.
Source: Dealroom company dataNews
Open roles
Neuromity Therapeutics in the Boston ecosystem
The Neuromity Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neuromity Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neuromity Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

